Dantrolene Sodium

CAS 24868-20-0 6 current records 1 historicalSmall Molecule

Who holds supplier records for Dantrolene Sodium? 6 organisations hold a current record for Dantrolene Sodium: an active US FDA Type II Drug Master File. A further 1 organisation has only historical (inactive) DMF filings. Recorded organisation countries for current records: India (2), Switzerland (1), China (1), Taiwan (1) and 1 other country (1).

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 13 Nov 2026. How we read these records

Cite as: PharmaTek, “Dantrolene Sodium: DMF and CEP holder records”, record as of 13 Nov 2026, pharmatek.co.uk/directory/api/dantrolene-sodium

Reading the evidence

  • 6 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • 2 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

Current records (6)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Dantrolene Sodium. Country is the organisation's recorded country, not necessarily the manufacturing site.

Need Dantrolene Sodium sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Historical records (1)

Organisations whose Type II DMFs for Dantrolene Sodium are no longer active. These show a past filing, not current supply.

Show all 1 historical record
  • India · Inactive DMF 17446 · filed May 2004

Other forms of this substance

A DMF or CEP is listed under the form it names. Salts, esters and hydrates of the same active substance have their own records:

Overview

Dantrolene Sodium is a muscle relaxant used to manage spasticity (muscle stiffness and spasms) and is crucial in the treatment of malignant hyperthermia. It acts by interfering with the release of calcium ions from the sarcoplasmic reticulum of skeletal muscles.

Chemical identity

IUPAC name
disodium;bis(3-[(E)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]-2-oxo-4H-imidazol-5-olate);heptahydrate
Canonical SMILES
C1N(C(=O)N=C1[O-])/N=C/C2=CC=C(O2)C3=CC=C(C=C3)[N+](=O)[O-].C1N(C(=O)N=C1[O-])/N=C/C2=CC=C(O2)C3=CC=C(C=C3)[N+](=O)[O-].O.O.O.O.O.O.O.[Na+].[Na+]
InChIKey
LTWQNYPDAUSXBC-CDJGKPBYSA-L
Synonyms
Dantrium API, dantamacrin, dantrium, dantrolen, dantrolene sodium hemiheptahydrate, dantrolene sodium heptahydrate, dantrolene sodium hydrate, dantrolene sodium salt hemiheptahydrate, f-440, nsc-758403, ryanodex

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Skeletal Muscle Relaxant
Physiologic effect
Decreased Striated Muscle Contraction; Decreased Striated Muscle Tone

Therapeutic areas

Neuromuscular DisordersSpasticityMalignant Hyperthermia

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Dantrolene Sodium?

6 organisations hold an active US FDA Type II Drug Master File or a CEP for Dantrolene Sodium: BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITED (India), GLAND PHARMA LTD (India), HAS Healthcare Advanced Synthesis SA (Switzerland), JINAN JINDA PHARMACEUTICAL CHEMISTRY CO LTD (China), SCINOPHARM TAIWAN LTD (Taiwan) and VERANOVA LP (United Kingdom). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Dantrolene Sodium Drug Master Files are active?

BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITED (DMF 33845), GLAND PHARMA LTD (DMF 39305), HAS Healthcare Advanced Synthesis SA (DMF 19498), JINAN JINDA PHARMACEUTICAL CHEMISTRY CO LTD (DMF 15167), SCINOPHARM TAIWAN LTD (DMF 16118) and VERANOVA LP (DMF 20779). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

What do the historical Dantrolene Sodium records mean?

1 organisation has only inactive Type II DMFs for Dantrolene Sodium. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

How do I qualify a Dantrolene Sodium supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Dantrolene Sodium?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.